title: Pharmacogenetics in major depression: a comprehensive meta-analysis.
abstract: A number of candidate gene studies focused on major depression (MD) and antidepressant (AD) efficacy have been carried out, but results mainly remain inconclusive. We performed a comprehensive meta-analysis of published candidate gene studies focused on AD efficacy in MD to evaluate the cumulative evidence. A random-effect model was applied to study the polymorphisms with genotypic counts available from at least three independent studies. On the base of previous evidence, the analysis was stratified by ethnicity (Caucasian, Asian, and other/mixed), and AD class (SSRIs and mixed/other ADs). Genotypic data were available for 16 polymorphisms in 11 genes. After the exclusion of 5-HTTLPR in SLC6A4 included in another recent meta-analysis, 15 polymorphisms in 11 genes were included in the present meta-analysis (BDNF rs6265, SLC6A4 STin2, HTR1A rs6295, HTR2A rs6311, rs6313 and rs7997012, HTR6 rs1805054, TPH1 rs1800532, SLC6A2 rs5569, COMT rs4680, GNB3 rs5443, FKBP5 rs1360780 and rs3800373, and ABCB1 rs1045642 and rs2032582). Our results suggested that BDNF rs6265 (Val66Met) heterozygous genotype was associated with better SSRIs response compared to the homozygous genotypes, particularly in Asians (OR=1.53, 95%CI 1.12-2.07, p=0.007). SLC6A4 STin2, HTR2A rs6311 and rs7997012, GNB3 rs5443, FKBP5 rs1360780 and rs3800373, and ABCB1 rs2032582 showed associations with AD efficacy, but these results were highly dependent on one or two single studies. In conclusion, our findings suggested the BDNF Val66Met as the best single candidate involved in AD response, with a selective effect on SSRI treatment. Our overall results supported no major effect of any single gene variant on AD efficacy.
authors.affiliation: Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.
authors.forename: Tomihisa
authors.initials: T
authors.lastname: Niitsu
authors.forename: Chiara
authors.initials: C
authors.lastname: Fabbri
authors.forename: Francesco
authors.initials: F
authors.lastname: Bentini
authors.forename: Alessandro
authors.initials: A
authors.lastname: Serretti
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D044466:Asian People / Q000235:genetics; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics; D002986:Clinical Trials as Topic; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics*; D056726:Genetic Association Studies; D006801:Humans; D008957:Models, Genetic; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics; D016896:Treatment Outcome; D044465:White People / Q000235:genetics
chemical_list: D000928:Antidepressive Agents; D019208:Brain-Derived Neurotrophic Factor
keywords: AD(s); Antidepressant; GENDEP; GWAS; Genome-based Therapeutic Drugs for Depression; LD; MARS; MD; MDD; Major depressive disorder; Meta-analysis; Munich Antidepressant Response Signature Project; Polymorphism; Remission; Response; STAR*D; Sequenced Treatment Alternatives to Relieve Depression; antidepressant(s); genome-wide association study; linkage disequilibrium; major depression; major depressive disorder